MedTrace Logo

Feasibility and Accuracy of Nanosensor-based Cancer Diagnosis at the Point-of-care (Chedza)

NCT04119154 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 270

Last updated 2022-05-02

No results posted yet for this study

Summary

Prospective feasibility and validation study of a novel, near-to-care modality for diagnosis of malignancy among cancer suspects.

Conditions

Interventions

DIAGNOSTIC_TEST

Contrast Microhalography (CEM)

Fine needle aspirates evaluated by CEM device

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Botswana Harvard AIDS Institute Partnership

    collaborator OTHER

  • Massachusetts General Hospital

    collaborator OTHER

  • Brigham and Women's Hospital

    collaborator OTHER

  • Harvard School of Public Health (HSPH)

    lead OTHER

Principal Investigators

  • Ralph Weissleder, MD, PhD · Massachusetts General Hospital

  • Scott Dryden-Peterson, MD, MSc · Botswana Harvard AIDS Institute, Harvard TH Chan School of Public Health, Brigham and Women's Hospital

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-01
Primary Completion
2021-09-20
Completion
2021-09-20

Countries

  • Botswana

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04119154 on ClinicalTrials.gov